Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer progression through regulating H3K9me3/p21 activity

Cell Death Dis. 2017 May 4;8(5):e2766. doi: 10.1038/cddis.2017.165.

Abstract

MDIG is known to be overexpressed in many types of human cancers and has demonstrated predictive power in the prognosis of cancer, although the functions and mechanisms of MDIG in liver cancer, especially in hepatocellular carcinoma (HCC), are still unknown. In this study, we report that MDIG and MYC were negatively regulated by IKZF1. MDIG overexpression substantially promoted HCC cell proliferation, cell migration and spreading, whereas knockdown of MDIG would reverse above-mentioned effect. MDIG effects on tumour cell growth were further demonstrated in a tumour xenograft model. Moreover, MDIG had effects on the level of p21(CIP1/WAF1) via H3K9me3 expression in HCC. MDIG was also found to be closely related to the sorafenib resistance of HCC cells in vitro. Clinically, we found that MDIG was frequently overexpressed in human HCCs (69.7%; n=155) and was significantly associated with histological grade and hepatitis B virus infection. Our findings indicate that MDIG plays an important role in HCC progression via MDIG/H3K9me3/p21(CIP1/WAF1) signalling and serves as a potential therapeutic target.

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / metabolism
  • Carcinoma, Hepatocellular / pathology*
  • Cell Line, Tumor
  • Cell Proliferation
  • Cyclin-Dependent Kinase Inhibitor p21 / metabolism*
  • Dioxygenases
  • Disease Progression
  • Histone Demethylases
  • Histones / metabolism*
  • Humans
  • Ikaros Transcription Factor / antagonists & inhibitors
  • Ikaros Transcription Factor / genetics
  • Ikaros Transcription Factor / metabolism*
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / metabolism
  • Liver Neoplasms / pathology*
  • Methylation
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Niacinamide / analogs & derivatives
  • Niacinamide / therapeutic use
  • Nuclear Proteins / antagonists & inhibitors
  • Nuclear Proteins / genetics
  • Nuclear Proteins / metabolism*
  • Phenylurea Compounds / therapeutic use
  • Promoter Regions, Genetic
  • Proto-Oncogene Proteins c-myc / genetics
  • Proto-Oncogene Proteins c-myc / metabolism*
  • Signal Transduction
  • Sorafenib
  • Transplantation, Heterologous

Substances

  • Antineoplastic Agents
  • Cyclin-Dependent Kinase Inhibitor p21
  • Histones
  • IKZF1 protein, human
  • Nuclear Proteins
  • Phenylurea Compounds
  • Proto-Oncogene Proteins c-myc
  • Ikaros Transcription Factor
  • Niacinamide
  • Sorafenib
  • Dioxygenases
  • Histone Demethylases
  • RIOX2 protein, human